Observational studyJournal of paediatrics and child health2026
Impact of Nirsevimab on Respiratory Syncytial Virus PCR Test Positivity in Young Infants: A Community-Level Observational Study in Queensland, Australia.
Observational study in Journal of paediatrics and child health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn April 2024 nirsevimab, a long-acting respiratory syncytial virus (RSV)-specific monoclonal antibody, was made available free of charge to all newborn infants in Queensland. We aimed to explore the community-level impact of a nirsevimab-based prevention program on RSV detection percentages among infants aged ≤ 3 months in Queensland, Australia.
methodsA retrospective analysis of January 2022-December 2024 laboratory data from a Queensland network. Weekly percentages of RSV-positive tests among infants aged ≤ 3 months (eligible group for nirsevimab) were compared with children aged 24-35 months (ineligible group) after nirsevimab introduction in mid-April 2024, and with comparable age data from 2022 to 2023.
resultsOverall, 20 956 RSV polymerase chain reaction tests for both age groups were performed during the study period (2022: 5593; 2023: 4910; 2024: 10 453). Following nirsevimab introduction, the percentage of RSV positive tests declined from 16.0% (370/2316) to 5.8% (51/876) among eligible infants (aged ≤ 3 months), compared to 18.6% (1879/10 098) to 14.6% (1117/7666) among ineligible children (aged 24-35 months). Difference-in-differences analysis showed an absolute risk difference of -6.9 percentage points (95% confidence interval: -13.2 to -4.1, p = 0.03).
conclusionsWe present the first real-world community-based evidence on the impact of nirsevimab upon RSV detection percentages in infants aged ≤ 3 months in Queensland, Australia. The nirsevimab-based prevention program may be contributing to a substantial decline in RSV detection percentages among young infants in the community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.